IMMUNOTHERAPY

During a live event, Mark Yarchoan, MD, and participants reviewed adverse event management for 3 different combination regimens for hepatocellular carcinoma.

Immunotherapy shows promise in reducing recurrence rates for high-risk skin cancer, despite mixed results in recent clinical trials.

Ravindra Uppaluri, MD, PhD, discusses findings from the KEYNOTE-689 trial in adult patients with resectable, locally advanced head and neck squamous cell carcinoma.

Ravindra Uppaluri, MD, PhD, discusses the background regarding locally advanced head and neck cancer and what the trial design of KEYNOTE-689 entailed.

Nivolumab plus ipilimumab showed activity in mCRPC, and while adding SBRT was safe, it did not boost efficacy in the CheckPRO trial.

Shlomo Koyfman, MD, discusses the MK-3475-630/​KEYNOTE-630 trial, which focused on patients with high-risk cutaneous squamous cell cancer.

Trials of IFx-Hu2.0 are initiating, looking to overcome checkpoint inhibitor resistance in Merkel cell carcinoma.

LBL-007 plus toripalimab showed manageable safety and favorable response in advanced solid tumors, notably higher in IO-naive nasopharyngeal carcinoma. Higher LAG-3 was linked to better responses.

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety profile with strong antitumor evidence.

A study in Nature Communications found that older cancer patients have similar outcomes with immune checkpoint inhibitors as younger patients, despite having different baseline immune profiles, suggesting potential for age-tailored therapies.

This approach aims to improve treatment for patients with this highly aggressive and treatment-resistant type of breast cancer.

OST-HER2 led to significant 12-month event-free survival and demonstrated favorable overall survival trends at 1 and 2 years in recurrent, fully resected osteosarcoma and lung metastases.

R-5780, an oral immuno-oncology drug designed to activate gut-regulated immune pathways, will now be evaluated in a phase 1 trial for cancer treatment.

The C-POST trial has shown cemiplimab to significantly improve disease-free survival in patients with high-risk cutaneous squamous cell carcinoma following surgery.

The phase 2 trial showed a 42% response rate with lete-cel in synovial sarcoma and MRCLS, with manageable adverse events.

The dual T-cell agonist invikafusp alfa achieved a 50% DCR in heavily pretreated anti–PD-1/PD-L1–resistant tumors, per findings at the 2024 SITC Annual Meeting.

Joe DePinto, MBA, discussed the findings of the McKesson 2024 Cell and Gene Therapy Report, providing insight into the challenges and opportunities in equitable access to these treatments.

Saro H. Armenian, DO, MPH, discussed the unique challenges facing children diagnosed with cancer and their families and what lies on the horizon.

Ryan Motte, PharmD, CSP, reviewed the global cancer burden among men and its projected trajectory to 2050, highlighting the role specialty pharmacies can play in combating this issue.

Alexa Simon Meara, MD, discusses the importance of including a rheumatology approach to immunotherapy treatment for cancer.

The combination of HBI-8000 and nivolumab induced a response in nearly two-thirds of patients with advanced melanoma and no prior anti–PD-1/PD-L1 treatment.

Joe DePinto, MBA, discusses some of the key challenges to equitable access to cell and gene therapies, especially in underserved populations.

The subcutaneous version of the cancer treatment atezolizumab is approved in all adult intravenous indications, including in lung, liver, and skin cancers.